Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS1168 in Adult Classical Phenylketonuria
NCT07318909Phase 1Not yet recruiting
- Sponsor
- Gritgen Therapeutics Co., Ltd.
- Start
- Dec 2027
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GS1168 in phenylketonuria (PKU), sponsored by Gritgen Therapeutics Co., Ltd. Primary endpoint: Incidence of adverse events at 52 weeks. Planned start Dec 2027; status: not yet recruiting.
02
Drugs
GS1168
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT07318909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318909.